Senseonics Holdings, Inc. (SENS) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Senseonics Holdings (SENS) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. The thesis rests on Eversense, the only long-term implantable continuous glucose monitor (CGM), which is now sold as Eversense 365, a sensor worn for a full year versus the 10-to-15-day patches from larger rivals. The biggest risk is scale: Senseonics is a small, unprofitable company competing against Dexcom and Abbott, and it continues to burn cash and rely on outside financing, which can dilute existing shareholders. As of October 16, 2026 the stock closed at $8.18, up about 39% year to date and about 63% over three months, though down about 15% in the past month, for a market value near $430 million.
SENS stock price
As of 2026-11-16, Senseonics Holdings, Inc. (SENS) last closed at $10.90, up 84.7% over the past year. Over the past 52 weeks it has traded between $4.86 and $10.90.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Senseonics Holdings, Inc.'s investor relations page. Walnut is informational, not investment advice.
SENS key stats
At $10.90 on November 16, 2026, Senseonics Holdings, Inc. (SENS) has a market cap of $576M.
- Market cap
- $576M
- Price to book
- 7.7
Market cap, P/E and yield are measured at the $10.90 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Senseonics Holdings, Inc. (SENS)?
The last two weeks for Senseonics Holdings, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- SENS closed at $10.90 on November 16, 2026, up 11.2% over the past five trading days (from $9.80).
- On November 9, 2026, Senseonics Holdings, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 9, 2026, Senseonics Holdings, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
- On November 10, 2026, Stifel raised its target to $10.00 from $9.00 (Hold).
- On November 10, 2026, Barclays raised its target to $11.00 from $10.00 (Equal-Weight).
- On November 10, 2026, HC Wainwright & Co. kept its Buy rating and $14.00 target.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Senseonics Holdings, Inc. (SENS) latest quarter
Senseonics reported revenue of $19.6 million for Q3 2026, up 142% from a year earlier (Senseonics, Nov 9, 2026).
Source: Senseonics Q3 2026 results, Nov 9, 2026. Full earnings breakdown
What does Senseonics Holdings, Inc. (SENS) do?
Senseonics Holdings develops and commercializes Eversense, a continuous glucose monitoring system for people with diabetes built around a small sensor implanted just under the skin of the upper arm. Unlike the disposable adhesive sensors from Dexcom and Abbott that last roughly 10 to 15 days, Eversense is designed for long-term wear, and the current Eversense 365 version is approved for up to one year on a single sensor, paired with a removable transmitter and a phone app. The long-wear, low-maintenance profile is the company's core differentiator in an otherwise patch-dominated category.
The numbers have moved quickly in 2026. Second-quarter revenue was about $14.5 million, up roughly 120% year over year, with US revenue up more than 150% while revenue outside the US grew only about 12% on tender delays. Gross margin reached 59%, and management raised full-year 2026 revenue guidance to $62-66 million and gross margin guidance to 58-61%. The cost of taking sales in-house shows up below that line: the second-quarter net loss widened to about $36.7 million from about $14.5 million a year earlier as SG&A rose to about $32.9 million, and the company expects 2026 operating expenses of $150-160 million and cash use of $110-120 million. A capital raise lifted cash to about $143 million at June 30, 2026, against about $63 million of debt. In September 2026 Senseonics signed a partnership with Beta Bionics to pair Eversense 365 with the iLet Bionic Pancreas automated insulin delivery system, with integration work expected to finish in the fourth quarter of 2026 and a commercial launch to follow, subject to testing and regulatory requirements. The next-generation Gemini sensor study is expected to complete by the end of 2026, with a 510(k) submission planned for the first quarter of 2027.
What's driving Senseonics Holdings, Inc. (SENS)?
Eversense 365 one-year differentiation
Eversense 365 extends sensor life to a full year, a meaningfully different experience from the 10-to-15-day disposable patches sold by larger competitors. Fewer replacements and an implantable form factor give the product a distinct position with users who want less frequent maintenance, and management has tied recent growth in new patient starts and improving gross margin to 365 adoption.
Bringing commercialization in-house from Ascensia
Eversense was historically distributed through a partnership with Ascensia Diabetes Care. Senseonics has been transitioning commercial, sales, and distribution rights back in-house in both the U.S. and Europe. Eliminating the revenue share with Ascensia is intended to lift gross margin and give the company direct control of marketing, though it also adds operating expense as it builds that infrastructure.
A large and growing CGM market
Continuous glucose monitoring continues to expand as use spreads beyond insulin-dependent diabetes toward broader type 2 and prediabetes populations. Senseonics is also pursuing automated insulin delivery (AID) integrations and a next-generation sensor program. A small share of a large, growing category is the bull framing, but capturing it requires execution against entrenched incumbents. The September 2026 Beta Bionics agreement is the most concrete AID step so far: Eversense 365 is being integrated with the iLet Bionic Pancreas, with integration expected to complete in the fourth quarter of 2026.
Margin and revenue inflection underway
Reported revenue grew sharply in 2025 and into 2026 as Eversense 365 ramped and the Ascensia revenue share rolled off, with gross margin improving from near breakeven. Second-quarter 2026 revenue rose about 120% with a 59% gross margin, and management raised full-year 2026 revenue guidance again to $62-66 million, though the business is still operating at a substantial net loss.
Gemini, the next-generation sensor
Senseonics' Gemini program is the follow-on to Eversense 365. Management said in August 2026 that the Gemini study should complete by the end of 2026, with a 510(k) submission planned for the first quarter of 2027 and data expected by the ADA meeting in 2027. Timelines like these often slip in medical devices, so the program is upside to the current story rather than part of reported results.
What are the risks to Senseonics Holdings, Inc. (SENS)?
Senseonics competes against Dexcom and Abbott, both far larger, profitable, and better capitalized, and either can press on price, reimbursement access, or product cadence. Scale is small, so a single reimbursement decision, manufacturing issue, or slower-than-expected patient adoption can move results materially. The company remains unprofitable and burns cash, so it has relied on equity and debt financing that can dilute shareholders. Reimbursement and regulatory outcomes across the U.S. and Europe add further uncertainty. The 2026 figures make the trade-off concrete: trailing revenue of about $49 million against a trailing net loss of about $109 million, guided 2026 cash use of $110-120 million against about $143 million of cash at mid-year, and international revenue that grew only about 12% in the second quarter. The stock is volatile in both directions, up about 63% over three months to mid-October 2026 but down about 15% in the final month.
What is the Senseonics Holdings, Inc. (SENS) forecast?
6 analysts publish price targets on SENS, averaging $13.83 as of November 2026, or +26.9% against the $10.90 share price on November 16, 2026. The published targets run from $9.00 to $18.00, a moderate spread, and the ratings split 4 buy, 3 hold, 1 sell. Over the last six months there have been 3 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full SENS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is SENS a buy or a sell?
We give no verdict on Senseonics Holdings, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Eversense 365 one-year differentiation. Eversense 365 extends sensor life to a full year, a meaningfully different experience from the 10-to-15-day disposable patches sold by larger competitors. The most optimistic published target, $18.00, assumes this works close to its best case.
The case against. Senseonics competes against Dexcom and Abbott, both far larger, profitable, and better capitalized, and either can press on price, reimbursement access, or product cadence. The most pessimistic target, $9.00, is roughly what SENS is worth if this bites instead.
Read the full bull and bear case on SENS, including what would have to change to break either one. Walnut is not an investment adviser.
Has Senseonics Holdings, Inc. (SENS) split its stock?
Yes. Senseonics Holdings, Inc. (SENS) has had one share split in the last 10 years:
- 1:20 on October 20, 2025, so every share held became 0.05 shares.
A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of SENS the day before the 1:20 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.
Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.
How is Senseonics Holdings, Inc. (SENS) valued?
Market cap, P/E and dividend yield at today's price are in the SENS key stats above. The business figures below come from Senseonics Holdings, Inc.'s reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$48.6M (FY2025 ~$35.3M)
- Q2 2026 revenue: ~$14.5M (up ~120% year over year)
- Full-year 2026 revenue guidance: ~$62M to $66M (raised in August 2026)
- Gross margin: 59% in Q2 2026; 2026 guidance 58-61%
- Net loss: ~$36.7M in Q2 2026; ~$109M TTM (Q2 EPS -$0.63 vs -$0.62 consensus)
- Cash and debt: ~$143M cash vs ~$63M debt (June 30, 2026)
As of October 2026: These figures describe a speculative growth company, not a mature one: revenue is rising quickly off a small base while net losses remain large relative to sales, and the market values it at roughly 9 times trailing revenue with no earnings to measure. Cash of about $143 million after the 2026 raise covers roughly one year of guided cash use, so further capital raises are possible. Third-quarter results are due November 4, 2026, with consensus at about $16.2 million of revenue and a loss of about $0.52 a share. All figures are approximate and tied to the asOf date; verify against the latest filings before acting.
Who competes with Senseonics Holdings, Inc. (SENS)?
Dexcom (DXCM)
The CGM market leader, selling the G-series and the over-the-counter Stelo sensors. Far larger, profitable, and well funded, with broad reimbursement and a deep installed base. Its sensors are disposable and worn for roughly 10 to 15 days rather than implanted, which is the core experiential contrast with Eversense.
Abbott (ABT) FreeStyle Libre
Abbott's FreeStyle Libre is the highest-volume CGM platform globally, backed by a diversified medical-device giant. Libre's low cost and wide availability make it a formidable competitor on price and access, and Abbott also markets the over-the-counter Lingo and Libre Rio sensors to broader consumer audiences.
Medtronic and other diabetes-tech players
Medtronic's Diabetes business pairs CGM sensors with insulin pumps and automated insulin delivery systems, and other entrants are pursuing CGM and integrated diabetes management. These companies compete for the same patients, clinicians, and payer coverage that Senseonics needs to win to scale Eversense.
What stocks are similar to Senseonics Holdings, Inc. (SENS)?
Other names that sit close to SENS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Senseonics Holdings, Inc. (SENS)
There are three common ways to get SENS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SENS sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where SENS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Senseonics Holdings, Inc. (SENS)
If you believe a once-a-year implantable sensor is a durable point of differentiation in the crowded CGM market and that Senseonics can keep growing patient starts while improving margins after taking commercialization in-house, then SENS is a way to express that view. It remains a speculative small-cap (about $430 million in market value in October 2026): revenue is still modest, net losses are large, and the company faces two far bigger and better-funded competitors. Position sizing and risk tolerance matter more here than with an established profitable company, and the descriptive purpose of this page is to explain how to invest, not whether you should.
More on Senseonics Holdings, Inc. (SENS)
Whether SENS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SENS a buy or a sell?, and where the stock could go from here in the SENS stock forecast.
For income investors, whether SENS pays a dividend and how the payout looks is covered in does SENS pay a dividend? And to weigh SENS against a peer, read the full side-by-side comparisons: SENS vs DXCM and SENS vs ABT.
Wondering how SENS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Senseonics Holdings, Inc.
Ask Walnut's AI anything about SENS and see how it fits what you own.
FAQ
What does Senseonics do?
+
Senseonics develops and sells Eversense, a continuous glucose monitor for people with diabetes. Its differentiator is an implantable sensor placed just under the skin of the upper arm that is worn long term, with the current Eversense 365 version approved for up to one year, paired with a removable transmitter and a smartphone app.
Is SENS a good stock to buy right now?
+
That depends on your own goals and risk tolerance, and this page does not give advice. The bull case is a genuinely differentiated one-year implantable CGM in a large, growing market with rising revenue and improving margins. The bear case is heavy competition from Dexcom and Abbott, ongoing losses, small scale, and dilution risk from future financing.
Is SENS profitable?
+
No. Senseonics is not profitable. It reported a net loss of roughly $69 million for full-year 2025 and wider losses of about $32 million in the first quarter of 2026 and about $37 million in the second as it took commercialization in-house, for a trailing loss of about $109 million. Revenue is growing quickly off a small base, but expenses still exceed sales, which is typical of an early-stage medical-device company.
Does SENS pay a dividend?
+
No. Senseonics does not pay a dividend (yield 0% as of October 2026). It is an unprofitable, growth-stage medical-device company that reinvests its capital into commercializing Eversense 365, building its in-house sales infrastructure, and funding its product pipeline. Investors in SENS would be looking for potential share-price appreciation rather than dividend income, and that potential is speculative.
What is Eversense 365?
+
Eversense 365 is the latest version of Senseonics' continuous glucose monitor, designed for a sensor worn up to a full year before replacement. That contrasts with the roughly 10-to-15-day disposable patch sensors from Dexcom and Abbott. The longer wear and implantable design are the core of the company's product differentiation and recent revenue growth.
What is the Ascensia partnership?
+
Ascensia Diabetes Care has been Senseonics' commercial partner for distributing and marketing Eversense. Senseonics has been transitioning those commercial and distribution rights back in-house in the U.S. and Europe. Removing the Ascensia revenue share is intended to improve gross margin and give Senseonics direct control of sales and marketing, while adding operating costs as it builds that capability.
How is SENS different from Dexcom and Abbott?
+
Dexcom and Abbott sell disposable adhesive CGM sensors worn for about 10 to 15 days. Senseonics' Eversense uses a sensor implanted under the skin that lasts much longer, up to a year with Eversense 365. The trade-off is a small in-office insertion procedure versus self-applied patches. Dexcom and Abbott are far larger and profitable; Senseonics is a small-cap challenger.
How can I buy SENS stock?
+
SENS is listed on the Nasdaq Global Select Market, according to Yahoo Finance as of October 2026, and can be bought through any major brokerage, including as fractional shares if your broker supports them. Some diversified or small-cap healthcare ETFs may hold it as a minor position. In Walnut you can also hold it as one constituent inside a thematic basket alongside related diabetes-tech or medical-device names.
How did Senseonics do in its latest quarter?
+
In the second quarter of 2026, Senseonics reported revenue of about $14.5 million, up roughly 120% year over year, with a 59% gross margin, and raised full-year revenue guidance to $62-66 million. The net loss widened to about $36.7 million, or $0.63 a share against a consensus loss of $0.62, as sales and marketing costs rose with the move away from Ascensia. Third-quarter results are scheduled for November 4, 2026.
How has SENS stock performed in 2026?
+
As of the October 16, 2026 close of $8.18, SENS was up about 39% year to date and about 63% over three months, but down about 15% over the past month and about 3% over one year. The 52-week range is $4.79 to $10.64. Swings this large are typical of a small, unprofitable device maker, and past moves do not predict future returns.
What is the Beta Bionics partnership?
+
Announced on September 14, 2026, it integrates Eversense 365 with Beta Bionics' iLet Bionic Pancreas, an automated insulin delivery system that does not require carb counting. Senseonics expects integration development to finish in the fourth quarter of 2026, with a commercial launch to follow subject to testing, validation and regulatory requirements. No financial terms were disclosed.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Senseonics Holdings, Inc.'s investor relations page or your broker before making investment decisions.